Literature DB >> 1985000

Enhancement of antibiotic concentrations in gastric mucosa by H2-receptor antagonist. Implications for treatment of Helicobacter pylori infections.

T U Westblom1, D E Duriex.   

Abstract

We measured the effects of cimetidine on antibiotic concentrations in the luminal portion of gastric mucosa. Guinea pigs were premedicated with cimetidine 4 mg/kg intramuscularly. Clindamycin, an antibiotic previously characterized under physiologic pH conditions, was administered intramuscularly and levels measured in serum and tissue using a high-pressure liquid chromatography (HPLC) technique. The luminal mucosa concentration of clindamycin at 1 hr (pH 5.9) was fivefold greater compared to the concentrations seen under physiologic (pH 2.0) conditions (81.5 micrograms/g vs 15.9 micrograms/g; P less than 0.05) and 10-fold greater at 2 hr (82.7 micrograms/g vs 8.09 micrograms/g; P less than 0.05). There was no difference in peak serum levels between the groups. The finding that an antibiotic with characteristics of a base is thus affected by a nonconservative acid inhibitor such as cimetidine supports the presence of an acidic storage pool as proposed by other investigators. H2-receptor antagonists may be useful therapeutic adjuncts in H. pylori infections by virtue of increasing gastric concentrations of antibiotics that behave as weak bases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985000     DOI: 10.1007/bf01300082

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

Review 1.  Chronic gastritis--a pathogenetic approach.

Authors:  J I Wyatt; M F Dixon
Journal:  J Pathol       Date:  1988-02       Impact factor: 7.996

Review 2.  Duodenal ulcer, Campylobacter pylori, and the "leaking roof" concept.

Authors:  C S Goodwin
Journal:  Lancet       Date:  1988 Dec 24-31       Impact factor: 79.321

3.  Invariant relation between total acid secretion and secretagogue exposure: secretory dynamics in bullfrog.

Authors:  E B Ekblad; V Licko
Journal:  Am J Physiol       Date:  1984-04

4.  Cellular site of gastric acid secretion.

Authors:  D R DiBona; S Ito; T Berglindh; G Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

5.  Omeprazole: inhibitor of both acid formation and translocation in gastric mucosa.

Authors:  E B Ekblad
Journal:  Acta Physiol Scand       Date:  1989-10

6.  Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study.

Authors:  P Unge; A Gad; H Gnarpe; J Olsson
Journal:  Scand J Gastroenterol Suppl       Date:  1989

7.  Thiocyanate and nitrite inhibit proton translocation in gastric mucosa.

Authors:  E B Ekblad; V Licko
Journal:  Biochim Biophys Acta       Date:  1985-07-11

8.  Guinea pig model for antibiotic transport across gastric mucosa: inhibitory tissue concentrations of clindamycin against Helicobacter pylori (Campylobacter pylori) following two separate dose regimens.

Authors:  T U Westblom; D E Duriex; E Madan; R B Belshe
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

9.  Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium.

Authors:  S L Hazell; A Lee; L Brady; W Hennessy
Journal:  J Infect Dis       Date:  1986-04       Impact factor: 5.226

10.  Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication.

Authors:  T J Borody; P Cole; S Noonan; A Morgan; J Lenne; L Hyland; S Brandl; E G Borody; L L George
Journal:  Med J Aust       Date:  1989-10-16       Impact factor: 7.738

View more
  8 in total

Review 1.  Helicobacter pylori and peptic ulcers: the present position.

Authors:  S Moss; J Calam
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

2.  Gastric penetration of amoxicillin in a human Helicobacter pylori-infected xenograft model.

Authors:  A Lozniewski; A Duprez; C Renault; F Muhale; M C Conroy; M Weber; A Le Faou; F Jehl
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

3.  Eradication of Helicobacter pylori with clarithromycin and omeprazole.

Authors:  R P Logan; P A Gummett; H D Schaufelberger; R R Greaves; G M Mendelson; M M Walker; P H Thomas; J H Baron; J J Misiewicz
Journal:  Gut       Date:  1994-03       Impact factor: 23.059

4.  Reduced amoxicillin uptake into human gastric mucosa when gastric juice pH is high.

Authors:  G Cardaci; J R Lambert; R G King; N Onishi; P Midolo
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

5.  Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state.

Authors:  L E Gustavson; J F Kaiser; A L Edmonds; C S Locke; M L DeBartolo; D W Schneck
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

6.  Dual therapy versus triple therapy for Helicobacter pylori-associated duodenal ulcers.

Authors:  J J Sung; S C Chung; T K Ling; R Suen; V K Leung; J Y Lau; A F Cheng; A K Li
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

Review 7.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

8.  Dual therapy trial using esomeprazole and amoxicillin as third-line rescue therapy for Helicobacter pylori infection.

Authors:  Hyun Kyung Park; Dong Ho Lee; Seungchul Suh; Pyoung Ju Seo; Nayoung Kim; Sook-Hyang Jeong; Jin-Wook Kim; Jin-Hyeok Hwang; Young Soo Park; Sang Hyub Lee; Cheol Min Shin
Journal:  Clin Endosc       Date:  2011-09-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.